Go Pro
NASDAQ:BRTX

Biorestorative Therapies Q2 2026 Earnings Report

Biorestorative Therapies logo
$2.51 -0.09 (-3.46%)
Closing price 09/24/2026 03:59 PM Eastern
Extended Trading
$2.49 -0.02 (-0.72%)
As of 09/24/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biorestorative Therapies EPS Results

Actual EPS
N/A
Consensus EPS
-$2.00
Beat/Miss
N/A
One Year Ago EPS
N/A

Biorestorative Therapies Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.60 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biorestorative Therapies Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Tuesday, September 29, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Biorestorative Therapies Earnings Headlines

Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
BioRestorative Therapies Announces Reverse Stock Split
See More Biorestorative Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biorestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biorestorative Therapies and other key companies, straight to your email.

About Biorestorative Therapies

Biorestorative Therapies (NASDAQ:BRTX) is a biotechnology company focused on developing regenerative medicine products using cell-based therapies. The company’s research programs are aimed primarily at treating musculoskeletal disorders and conditions associated with metabolic health.

Its principal product candidate is BRTX-100, an autologous cell therapy being developed for painful degenerative disc disease. The treatment is designed to use a patient’s own bone marrow-derived cells, which are processed and expanded before being administered to the affected spinal disc. BioRestorative has advanced BRTX-100 through clinical development and has evaluated its safety and potential effectiveness in patients with chronic lower-back pain.

The company is also developing ThermoStem, a cell therapy platform intended to generate brown adipose tissue for potential applications involving obesity and metabolic disorders. BioRestorative Therapies is based in the United States and conducts its development activities through research, clinical and regulatory programs. The company’s candidates remain subject to clinical testing and regulatory review, and their eventual availability and indications are not assured.

View Biorestorative Therapies Profile